You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

diffuse large B-cell lymphoma-activated B-cell (DLBCL-ABC)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Activated B-cell DLBCL (ABC DLBCL) Trial in United Kingdom, United States (Acalabrutinib)

Active, not recruiting
Has Results
  • Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL)
  • Los Angeles, California
  • +6 more
Dec 1, 2022

Non-Hodgkin's Lymphoma (NHL), Activated B-Cell Type DLBCL (ABC-DLBCL), Mantle Cell Lymphoma (MCL) Trial in Indianapolis, Spokane

Recruiting
  • Non-Hodgkin's Lymphoma (NHL)
  • +4 more
  • Indianapolis, Indiana
  • +1 more
Jul 12, 2022

Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
  • (no location specified)
Sep 5, 2023

Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

Recruiting
  • Diffuse Large B-cell Lymphoma Recurrent
  • Diffuse Large B Cell Lymphoma Refractory
  • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 12, 2023

DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Mitoxantrone Hydrochloride Liposome Injection
  • Jinan, Shandong, China
    Affiliated Cancer Hospital of Shandong First Medical University
May 16, 2023

DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in Xiamen (Lenalidomide combined with G-CHOP (LO CHOP))

Recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • Follicular Lymphoma
  • Lenalidomide combined with G-CHOP (LO CHOP)
  • Xiamen, Fujian, China
    Bing Xu
Nov 28, 2023

DLBCL Trial (Acalabrutinib, Rituximab)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • (no location specified)
Jul 11, 2023

Diffuse Large B Cell Lymphoma (DLBCL) Trial in Toronto (glofitamab)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Sep 18, 2023

Diffuse Large B Cell Lymphoma Trial in Tampa (Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Itacitinib
  • Chimeric antigen receptor (CAR) T-cell therapy
  • Tampa, Florida
    Moffitt Cancer Center
Mar 6, 2023

Frontline of ASCT in High-risk DLBCL

Recruiting
  • Diffuse Large B Cell Lymphoma
    • Beijing, Beijing, China
      Peking University People's Hospital
    Apr 26, 2023

    Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma:

    Completed
    • Diffuse Large B-cell Lymphoma
      • East Hanover, New Jersey
        Novartis
      Jun 16, 2023

      Non-GCB/ABC DLBCL, With and Without MyD88 and/or CD79B Mutations Trial in Cleveland, Toledo (Mivavotinib)

      Recruiting
      • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
      • With and Without MyD88 and/or CD79B Mutations
      • Evanston, Illinois
      • +6 more
      Dec 12, 2022

      Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)

      Not yet recruiting
      • Diffuse Large B-cell Lymphoma
      • (no location specified)
      Mar 23, 2023

      Diffuse Large B Cell Lymphoma,DLBCL Trial in Chengdu (PM 8.4 mg/m2, PM 11.2 mg/m2)

      Recruiting
      • Diffuse Large B Cell Lymphoma，DLBCL
      • PM 8.4 mg/m2
      • PM 11.2 mg/m2
      • Chengdu, Sichuan, China
        West China Hospital Sichuan University
      Jan 15, 2023

      DLBCL - Diffuse Large B Cell Lymphoma Trial in Toronto (Cyclophosphamide, TLI)

      Recruiting
      • DLBCL - Diffuse Large B Cell Lymphoma
      • Toronto, Ontario, Canada
        Princess Margaret Cancer Centre
      Jul 19, 2023

      Diffuse Large B-cell Lymphoma Trial in Hangzhou (Metabolically Armed CD19 CAR-T cells)

      Recruiting
      • Diffuse Large B-cell Lymphoma
      • Metabolically Armed CD19 CAR-T cells
      • Hangzhou, Zhejiang, China
        The first affiliated hospital of medical college of zhejiang uni
      Nov 1, 2023

      DLBCL Trial (Polatuzumab Vedotin)

      Not yet recruiting
      • Diffuse Large B-Cell Lymphoma
      • Polatuzumab Vedotin
      • (no location specified)
      Jul 12, 2023

      Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL

      Recruiting
      • Diffuse Large B Cell Lymphoma
        • Salvador, Bahia, Brazil
        • +9 more
        Jul 24, 2023

        Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

        Recruiting
        • Diffuse Large B Cell Lymphoma
        • +3 more
        • Low-Dose Decitabine plus anti-PD-1
        • Beijing, Beijing, China
          ChinaPLAGH
        Apr 18, 2023

        Including miRNA-based Tumor Signatures in Diffuse Large B Cell

        Not yet recruiting
        • Diffuse Large B Cell Lymphoma
        • Relapsed Non-Hodgkin Lymphoma
        • no intervention (observational study)
        • Napoli, Italy
        • +2 more
        Feb 17, 2023

        High-Dose Methotrexate Clearance in Diffuse Large B-Cell

        Recruiting
        • Central Nervous System Lymphoma
        • Diffuse Large B-Cell Lymphoma
        • Non-Interventional Study
        • Columbus, Ohio
          Ohio State University Comprehensive Cancer Center
        Sep 8, 2023

        Diffuse Large B Cell Lymphoma, Relapsed DLBCL, Refractory DLBCL Trial in Boston (Copanlisib, Venetoclax)

        Active, not recruiting
        • Diffuse Large B Cell Lymphoma
        • +2 more
        • Duarte, California
        • +2 more
        Nov 10, 2022

        Diffuse Large B Cell Lymphoma Trial in Shenyang (Zanubrutinib, Rituximab, Cyclophosphamide)

        Not yet recruiting
        • Diffuse Large B Cell Lymphoma
        • Shenyang, Liaoning, China
          Xing Xiaojing
        Jun 1, 2023

        Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

        Recruiting
        • Recurrent Diffuse Large B-Cell Lymphoma
        • Refractory Diffuse Large B-cell Lymphoma
        • RC19D2 cell injection
        • Tianjin, Tianjin, China
          Hematology Hospital of the Chinese Academy of Medical Sciences
        Sep 14, 2023

        Diffuse Large B Cell Lymphoma, DLBCL, Cancer Trial in Madison (Rituximab, Cyclophosphamide, Doxorubicin)

        Recruiting
        • Diffuse Large B Cell Lymphoma
        • +2 more
        • Madison, Wisconsin
          University of Wisconsin Carbone Cancer Center
        Dec 12, 2022